D. Boral Capital Reiterates Buy Rating for GeoVax Labs (NASDAQ:GOVX)

GeoVax Labs (NASDAQ:GOVX)‘s stock had its “buy” rating reissued by equities researchers at D. Boral Capital in a research report issued on Wednesday,Benzinga reports. They currently have a $18.00 price target on the stock.

Several other equities analysts have also commented on the company. Alliance Global Partners assumed coverage on GeoVax Labs in a research note on Monday, November 11th. They issued a “buy” rating and a $15.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 target price on shares of GeoVax Labs in a research report on Friday, November 15th. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, GeoVax Labs currently has an average rating of “Buy” and a consensus target price of $14.20.

GeoVax Labs Trading Up 3.6 %

NASDAQ:GOVX opened at $2.32 on Wednesday. The company’s 50-day moving average is $2.35 and its two-hundred day moving average is $2.75. GeoVax Labs has a 1-year low of $1.09 and a 1-year high of $11.18.

GeoVax Labs (NASDAQ:GOVX) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.91) EPS for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.38. The business had revenue of $2.79 million during the quarter, compared to analyst estimates of $1.84 million. During the same quarter in the prior year, the company posted ($4.80) earnings per share. Equities research analysts predict that GeoVax Labs will post -4.49 EPS for the current year.

Hedge Funds Weigh In On GeoVax Labs

An institutional investor recently bought a new position in GeoVax Labs stock. Virtu Financial LLC acquired a new stake in GeoVax Labs, Inc. (NASDAQ:GOVX) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 40,210 shares of the company’s stock, valued at approximately $97,000. Virtu Financial LLC owned 0.43% of GeoVax Labs as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 6.09% of the company’s stock.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.